Safety and immunogenicity of a 7-valent pneumococcal conjugate vaccine (Prevenar): primary dosing series in healthy Chinese infants (Q40423328)

20 September 2017

Safety and immunogenicity of a 7-valent pneumococcal conjugate vaccine (Prevenar): primary dosing series in healthy Chinese infants (English)

1 reference

pneumococcal conjugate vaccine

20 September 2017

1 reference

Rong Cheng Li

1

1 reference

20 September 2017

Feng Xiang Li

2

1 reference

20 September 2017

Yan Ping Li

3

1 reference

20 September 2017

Su Ying Guo

4

1 reference

20 September 2017

Yi Nong

5

1 reference

20 September 2017

Qiang Ye

6

1 reference

20 September 2017

Kong Xiong Fang

7

1 reference

20 September 2017

Shao Chao Wei

8

1 reference

20 September 2017

Zhiqian Wang

9

1 reference

20 September 2017

Stephen Lockhart

10

1 reference

20 September 2017

language of work or name

English

0 references

publication date

29 February 2008

1 reference

20 September 2017

1 reference

20 September 2017

26

1 reference

20 September 2017

18

1 reference

20 September 2017

2260-2269

1 reference

Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.029

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.029

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.029

Serotype distribution and antimicrobial resistance patterns in Streptococcus pneumoniae isolates from hospitalized pediatric patients with respiratory infections in Shanghai, China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.029

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.029

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.029

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.029

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.029

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.029

Population-based impact of pneumococcal conjugate vaccine in young children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.029

Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.029

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.029

Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.029

Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.029

Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.029

Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.029

10.1016/J.VACCINE.2008.02.029

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference